Randall Kaye
CIK 1350416 · Executive Vice President & CMO · last filed 2024-12-02
Randall Kaye is an Executive Vice President & CMO who has filed 46 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for LBPH, was dated Dec 2, 2024. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.35M
3
46
-$2.83M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Executive Vice President & CMO | 0 | $59.98 | $0 | -$2.09M | 9 | 2024-12-02 |
| AXSM | Chief Medical Officer | 11,044 | $212.74 | $2.35M | $9.0K | 2 | 2015-12-24 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | Sr. VP, Chief Medical Officer | 71,940 | — | — | -$745.7K | 33 | 2011-09-13 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-02 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Mixed | −30,554 | -$1.83M | EDGAR |
| 2024-11-19 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Exer (M) | +30,554 | $183.3K | EDGAR |
| 2024-10-29 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-10-16 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Mixed | — | -$911.4K | EDGAR |
| 2024-09-16 | — | Notice (144) | −33,333 | -$1.14M | EDGAR |
| 2024-09-16 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Mixed | — | -$454.8K | EDGAR |
| 2024-08-13 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Mixed | — | -$505.9K | EDGAR |
| 2024-08-12 | — | Notice (144) | −16,667 | -$584.8K | EDGAR |
| 2024-02-09 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Grant (A) | +17,920 | $0 | EDGAR |
| 2023-02-10 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.